NASDAQ:INAB

IN8bio (INAB) Stock Forecast, Price & News

$2.73

-0.42 (-13.33%)

(As of 06/5/2023 ET)

Compare

Today's Range: $2.56
▼
$3.05
50-Day Range: $1.05
▼
$3.24
52-Week Range: $1.02
▼
$3.95

Volume: 702,551 shs
Average Volume: 2.26 million shs
Market Capitalization: $81.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

IN8bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 205.3% Upside
$8.33 Price Target
Short Interest: Healthy
1.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.10) to ($1.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

685th out of 986 stocks

Biological Products, Except Diagnostic Industry

110th out of 165 stocks

3.3

Analyst's Opinion

Consensus Rating
IN8bio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.33, IN8bio has a forecasted upside of 205.3% from its current price of $2.73.
Amount of Analyst Coverage
IN8bio has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.14% of the float of IN8bio has been sold short.
Short Interest Ratio / Days to Cover
IN8bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IN8bio has recently decreased by 88.45%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
IN8bio does not currently pay a dividend.
Dividend Growth
IN8bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INAB.

2.6

News and Social Media Coverage

News Sentiment
IN8bio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for IN8bio this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IN8bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.80% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.24% of the stock of IN8bio is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IN8bio are expected to decrease in the coming year, from ($1.10) to ($1.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IN8bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IN8bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IN8bio has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IN8bio (NASDAQ:INAB) Stock

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

INAB Stock News Headlines

June 5, 2023 | finance.yahoo.com

IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross

June 5, 2023 | finance.yahoo.com

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

June 5, 2023 | markets.businessinsider.com

IN8bio (INAB) Gets a Buy from EF Hutton

May 24, 2023 | finance.yahoo.com

IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know

May 20, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for IN8bio, Inc. Issued By HC Wainwright (NASDAQ:INAB)

May 19, 2023 | americanbankingnews.com

Brokers Offer Predictions for IN8bio, Inc.'s Q1 2024 Earnings (NASDAQ:INAB)

May 17, 2023 | finance.yahoo.com

IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 12, 2023 | finance.yahoo.com

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023 | msn.com

Recap: IN8bio Q1 Earnings

May 2, 2023 | benzinga.com

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting

May 1, 2023 | finance.yahoo.com

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

April 26, 2023 | finance.yahoo.com

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting

April 26, 2023 | investorplace.com

Why Is IN8bio (INAB) Stock Up 9% Today?

April 26, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on IN8bio (INAB)

April 25, 2023 | seekingalpha.com

IN8bio wins FDA Orphan Drug designation for glioma candidates

April 25, 2023 | msn.com

Short Volatility Alert: In8bio Inc

April 25, 2023 | proactiveinvestors.com

IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment

April 25, 2023 | msn.com

IN8bio Shares Are Pulling Back Tuesday: What's Going On?

April 25, 2023 | finance.yahoo.com

IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

April 24, 2023 | msn.com

Why Are IN8bio Stock Is Soaring More Than 100% Today

April 24, 2023 | msn.com

IN8bio Soars after Promising Drug Data

April 21, 2023 | americanbankingnews.com

IN8bio (NASDAQ:INAB) Stock Rating Reaffirmed by EF Hutton Acquisition Co. I

April 17, 2023 | finance.yahoo.com

IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023

April 11, 2023 | finance.yahoo.com

IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting

April 1, 2023 | finanznachrichten.de

IN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

See More Headlines

INAB Price History

30 days | 90 days | 365 days | Advanced Chart

INAB Company Calendar

Last Earnings: 3/30/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INAB
CUSIP: N/A
CIK: 1740279
Web: www.in8bio.com
Phone: 646-600-6438
Fax: N/A
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.33
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +205.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -125.05%
Return on Assets: -94.12%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 3.84
Quick Ratio: 3.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.93 per share
Price / Book: 2.94

Miscellaneous

Outstanding Shares: 29,750,000
Free Float: 19,100,000
Market Cap: $81.22 million
Optionable: Not Optionable
Beta: 0.29

Key Executives

Mr. Tai-Wei Ho (Age 47)
Co-Founder, Pres, CEO & Director
Comp: $727.46k

Dr. Lawrence S. Lamb Ph.D. (Age 69)
Exec. VP, Co-Founder & Chief Scientific Officer
Comp: $482.47k

Mr. Patrick McCall CPA (Age 40)
CFO & Sec.
Comp: $519.35k

Dr. Kate Rochlin Ph.D. (Age 42)
Chief Operating Officer

Dr. Trishna Goswami M.D.
Chief Medical Officer

Dr. Kenneth R. LaMontagne Ph.D.
Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INAB Stock - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INAB shares.
View INAB analyst ratings or view top-rated stocks.
What is IN8bio's stock price forecast for 2023?: 3 Wall Street analysts have issued 1-year price objectives for IN8bio's shares. Their INAB share price forecasts range from $3.00 to $14.00. On average, they predict the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 205.3% from the stock's current price.
View analysts price targets for INAB or view top-rated stocks among Wall Street analysts.
How have INAB shares performed in 2023?: IN8bio's stock was trading at $2.31 at the start of the year. Since then, INAB stock has increased by 18.2% and is now trading at $2.73.
View the best growth stocks for 2023 here.
Are investors shorting IN8bio?: IN8bio saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 137,500 shares, a drop of 88.4% from the April 30th total of 1,190,000 shares. Based on an average trading volume of 3,630,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.1% of the company's shares are sold short.
View IN8bio's Short Interest.
When is IN8bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our INAB earnings forecast.
How were IN8bio's earnings last quarter?: IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings data on Thursday, March, 30th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04.

When did IN8bio IPO?: (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.
What is IN8bio's stock symbol?: IN8bio trades on the NASDAQ under the ticker symbol "INAB."
Who are IN8bio's major shareholders?: IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.82%) and Dimensional Fund Advisors LP (0.10%). Insiders that own company stock include Emily Fairbairn, Kate Rochlin, Lawrence Lamb, Trishna Goswami and William Tai-Wei Ho.
View institutional ownership trends.
How do I buy shares of IN8bio?: Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IN8bio's stock price today?: One share of INAB stock can currently be purchased for approximately $2.73.
How much money does IN8bio make?: IN8bio (NASDAQ:INAB) has a market capitalization of $81.22 million. The company earns $-28,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.
How can I contact IN8bio?: IN8bio's mailing address is 79 Madison Avenue, New York, New York 10016. The official website for the company is www.in8bio.com. The company can be reached via phone at 646-600-6438 or via email at dbuck@soleburytrout.com.

This page (NASDAQ:INAB) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial